NEC acquires Norwegian bioinformatics company, OncoImmunity
OncoImmunity AS will now become a subsidiary of NEC and operate under the name of NEC OncoImmunity AS. OncoImmunity AS, founded in 2014, is a bioinformatics company dedicated
OncoImmunity AS will now become a subsidiary of NEC and operate under the name of NEC OncoImmunity AS. OncoImmunity AS, founded in 2014, is a bioinformatics company dedicated
In the late-stage trial called KEYNOTE-522, Keytruda and chemotherapy combination achieved pathological complete response (pCR) following the neoadjuvant part of the neoadjuvant/adjuvant study regimen. pCR is defined as
AVT02 is a mAb biosimilar to AbbVie’s HUMIRA, which is a leading drug indicated for the treatment of several autoimmune diseases, including (but not limited to) Rheumatoid Arthritis
NeuroSTAT’s FDA Fast Track designation makes NeuroVive eligible, for example, for more frequent meetings and written communication with the FDA, continuous feedback on each section of its New
The committee has recommended the approval of Tecentriq plus chemotherapy (carboplatin and Abraxane [albumin-bound paclitaxel; nab-paclitaxel]) for the initial treatment of adults with metastatic non-squamous non-small cell lung
Under the terms of the agreement, Verastem Oncology shall receive an upfront payment of $5 million USD. Verastem Oncology is also eligible to receive up to an additional
Full Week 48 findings were presented today at the 10th International AIDS Society Conference on HIV Science (IAS 2019) in Mexico City. Kimberly Smith, MD, Head of Global
Ab Initio was a privately held antigen-discovery company based in South San Francisco, California. Antigen design and preparation are the first steps necessary for the discovery of therapeutic
The breakthrough therapy designation for the Keytruda, Lenvima combo is for the first-line treatment of patients with advanced unresectable HCC that is not responsive to locoregional treatment. Keytruda
The company said that the week 96 data from the two-cohort BRIGHTE trial revealed that fostemsavir continued to improve virologic suppression and immunologic response. Fostemsavir is a prodrug